

### Which are the trial phases


• Phase I: small number of patients (20-80) fpr pharmacovigilance, pharmacokinetics, pharmacodynamics

•Phase II: performed on larger groups (20-300) and designed to assess clinical efficacy of the therapy; as well as to continue Phase I assessments


•Phase III: randomized controlled trials on large patient groups (300-3000 or more depending upon the condition) and are aimed at being the definitive assessment of the efficacy of the new therapy, in comparison with current 'Gold Standard' treatment.

•Phase IV: involve the post-launch safety surveillance and ongoing technical support of a drug.

#### Clinical trials – 2016 update




#### Trials/continent



The Journal of Gene Medicine, © 2012 John Wiley and Sons Ltd

# Trials/country



1.1


2.2

 Number


 Italy
 25

 France
 52

# Gene therapy trial phases




## Which diseases with gene therapy




## Why such diseases

- Killing diseases(:::)
- Known gene
- Accessibility of the hit tissue
- Gene expression not crucial
- Clinically reversible state


## Which genes in gene therapy



#### Publications vs clinical trials in gene therapy



## Which vectors for the genes



#### http://www.abedia.com/wiley/index.html Inlas in Italy (registered 2013)

				virus/host		
Trial ID	Title	disease/transgene	phase	cell	lab	closed
	Treatment of Patients with Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency by Autologous Transplantation of Genetically		1		bordignon	
<u>IT-0001</u>	Modified T Cells	ADA/ADA	1/11		milan	1995
	Constructor into Parisheral Pland Lumphonite for In Vivo Immunamedulation of Denor Anti-Tumor Immunity in Patiente Affected by Resurrent Disease Affect	TK/graft versus host			bordignon	
<u>IT-0002</u>	Allogeneic BMT	disease	1/11		milan	1995
	Gene Transfer into Peripheral Blood Lymphocytes for In Vitro Immunosection and In Vivo Immunomodulation of Donor Anti-Tumor Immunity in Patients Affected by EBV-induced LPD Following Allogeneic BMT	TK/graft versus host	/		bordignon	
<u>11-0003</u>		disease	1/11		milan	1995
	Active Immunization of Metastatic Melanoma Patients with Interleukin-4 Transfected, Allogeneic Melanoma Cells. A Phase I?II Study				cascinelli	
<u>11-0004</u>		IL4/melanoma	1/11	retro	milan	1995
				retro/tum		
<u>IT-0005</u>	Gene Therapy for metastatic melanoma	IL2/melanoma	1/11	-	milan	open
				naked		1
IT-0006	Gene Therapy in Patients with Lymphoma and Leukemia			DNA/musc		
		?/leukemia, limphoma	1		fazio rome	open
				retro/tum		·
<u>IT-0007</u>	Active Immunization of Metastatic Melanoma Patients with Interleukin- 4 Transduced, Allogeneic Melanoma Cells. A Phase I? II Study	IL4/melanoma	1/11	or cell	milan	1997
IT-0008	Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloblative conditionining	ADA/ADA	1		aiuti milan	
			-		maio	
<u>IT-0009</u>	Gene therapy in patients with melanoma	IL4/melanoma	1		aviano	open
IT-0010	Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells	IL2/melanoma	1		belli milan	1997
	A phase I-II study of active vaccination with autologous T-lymphocytes transduced with HSV-TK and MAGE-A3 in patients with metastatic melanoma and expression of MAGE-A3		-	retro/auto		
<u>IT-0011</u>		TK/melanoma	1/11	logous	milan	open
	A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients with Cancers Expressing HER-2 and/or CEA			naked		
IT-0012		HER CEA/Colrectal cancer,		DNA/tumo	parmiani	
		lung cancer	1/11	r cell	milan	open
IT-0013	Pilot study of transfer of the FHIT gene into bronchial non-small cell lung cancers		.,		parmiani	
		Non-small cell lung cancer	1	Ad/ FHIT	milan	2002
	A phase I/II study of active vaccination with autologous T-lymphocytes transduced with HSV-TK and MAGE-A3 in patients with metastatic melanoma and			retro/auto		
<u>IT-0014</u>	expression of MAGE-A3	TK/melanoma	1/11	-	milan	open
	Study of the safety and efficacy of hematopoietic stem cells transduced with RevM10poIAS (RevM10poIAS HSCIP) as therapy for HIV-1 infected persons	HIV-1 RevM10	/	retro/auto		
<u>IT-0015</u>		HIV-1 polAS/HIV	1/11	-	milan	2003
				retro/CD3		
<u>IT-0016</u>	ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID	ADA/ADA	1/11	4	milan	open
IT-0018	phase III study: infusion of donor lymphocytes transduced with the suicide gene gene HSV-TK after transplantation of allogenic T-depleted stem cells from a					
11-0018	haploidentical donor in patients with haematological malignancies	TK/Leukemia		HSV		open
IT 0010		Arysulfate				
<u>II-0019</u>		A/Metachromatic				
		Leukodystrophy	1/11	lenti/-	biffi milan	
<u>11-0020</u>	Phase I/II study of hematopoietic stem cell gene therapy with Lentiviral Vectors for the treatment of Wiskott Aldrich Syndrome	/WAS gene	1/11		aiuti milan	open
IT-0021	TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia				ciceri	
		leukemia/tyrosinase		HSV	milan	open
IT-0022	Phase Ib Study to Assess the Safety and Immunogenicity of a Novel HCV Vaccine, Based on the Sequential Injection of Ad6NSmut and MVA-NSmut, Given in			Ad-ankara		
	Combination With PEG-Interferon Alfa Plus Ribavirin for Re-treatment of Chronic Hepatitis C	HCV/Nsmut	l	vaccine	pisa	open

## DNA as a drug, ideally...pros

- long term
- treatment of the cause
- specificity
- no side effects

# Potential risks of gene therapy

- Insertional mutagenesis leading to cancer
- Recombination of disabled vector resulting in environmental pollution by infectious recombinant virus
- Toxic shock caused by viraemia
- Transfer of non-viral exogenous material
- Contamination with other deleterious viruses or organisms
- Physiological effects of over-expression
- Germ-line transduction?